Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heat therapy plus pills could tame overactive thyroid

NCT ID NCT07557810

Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for treating hyperthyroidism (overactive thyroid) by combining a minimally invasive heat procedure with standard medication. About 454 adults with hyperthyroidism will receive thermal ablation to destroy overactive thyroid tissue, plus antithyroid drugs to control hormone levels. The goal is to see if this combination can better control symptoms, reduce drug side effects, and improve quality of life compared to medication alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 454 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The population receiving thermal ablation combined with antithyroid drug therapy for hyperthyroidism primarily includes patients diagnosed with hyperthyroidism (e.g., Graves' disease, toxic multinodular goiter, or toxic adenomas). These patients typically choose this combined approach due to inadequate response or intolerance to antithyroid drugs alone, refusal of radioactive iodine, or unsuitability/unwillingness for surgery. The combined strategy aims to ablate hyperfunctioning tissue while maintaining stable thyroid function with medication, preserving normal glandular tissue, avoiding lifelong replacement therapy, and achieving minimal scarring, rapid recovery, and short hospitalization. Candidates generally have moderate thyroid volumes and localized lesions amenable to ultrasound-guided ablation.

Ages

Up to 80 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with primary hyperthyroidism based on clinical manifestations and laboratory findings; * Patients whose basal metabolic rate (BMR) remains within ±20% of the normal reference range, and whose resting heart rate is controlled at ≤90 beats/min; * Patients with inadequate response to standard antithyroid drug (ATD) therapy, those experiencing severe adverse reactions to ATDs, those unsuitable for or unresponsive to radioactive iodine (RAI) therapy, or those who decline conventional surgical resection and wish to undergo ablation combined with medication to shorten the treatment course and achieve rapid improvement of hyperthyroid symptoms, including patients with mild, moderate, or severe disease; * Patients with concomitant moderate-to-severe Graves' ophthalmopathy (GO); * Patients with a safe needle trajectory for ablation access; * Patients who are able to understand the purpose of the study, voluntarily participate, and provide written informed consent. Exclusion Criteria: * Severe coagulopathy; * Poor general condition, such as concomitant severe cardiac, hepatic, renal, or other major organ dysfunction; * Substernal goiter or a thyroid gland largely located in the retrosternal space (relative contraindication; staged treatment may be considered); * Patients with malignant exophthalmos in whom the condition may worsen post-procedure; * Patients with significant tracheal compression requiring urgent decompression; * Unilateral vocal cord dysfunction confirmed by laryngoscopy; * Women in the first or third trimester of pregnancy, lactating women, or those planning pregnancy in the near future.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Complication rate are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperthyroidism primary hyperthyroidism thyrotoxicosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Complication rate Cure rate Efficacy and safety Hyperthyroidism/thyrotoxicosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.